GERON CORP Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
GERON CORP (GERN) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $45.98 billion as of 2025-09-30, per its 10-Q filed 2025-11-07.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2025-11-07
- 2025-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $45.98B.
- 2025-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $42.18B.
- 2025-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $45.47B.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2025-09-30 | $45.98B 10-Q · filed 2025-11-07 |
| 2025-06-30 | $42.18B 10-Q · filed 2025-08-06 |
| 2025-03-31 | $45.47B 10-Q · filed 2025-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |